Sentences with phrase «effects of drug therapy»
The study's co-first authors Caroline Gallant and Spyros Darmanis highlight the ability of their approach to finely identify the differential effects of drug therapy on cell types that up to now have been difficult to distinguish.
http://www.scilifelab.se/
He has co-authored more than 100 scientific papers, abstracts, and letters examining the efficacy, safety and effects of drug therapies for cancer.
Eventually, the spinal - tap method could look for elevated amyloid - beta in people with early symptoms of suspected Alzheimer's or measure the effects of drug therapies on already - diagnosed patients.
Those who test animals to determine the effects of drug therapies also need excellent diagnostic skills.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Many would argue that it's possible for her to feel better without taking drugs: she could try the «talking cure» (regular sessions with a counselor), or an alternative treatment such as herbal or light therapy If she goes to an M.D., though, she'll likely carry my a prescription for an antidepressant such as Prozac or Zoloft — one of these brave new medicines that promise such good results with so few side effects,
After suffering from the terrible side effects of steroids, antibiotics, and immunosuppressant drug therapy, I decided to do some research of my own and I soon discovered that my symptoms could be controlled simply by the food I put in my body.
Disney said the precise binding of Targapremir - 18a to microRNA - 18a means a cancer drug that follows this strategy would be likely to kill prostate cancer cells without causing the broader side effects seen with many other cancer therapies.
«Targeting FAS - ligand could be a good adjunct therapy to boost the effects of immunotherapeutic drugs.»
While the once - daily dosing, low side - effects profile, and shortened treatment duration of interferon - free direct - acting antivirals are ideal for injection drug users, most trials of these therapies for HCV have excluded persons with recent injection drug use.
«Because we observed microbial effects mainly in the gut, we believe that a microbe - based therapy would avoid the collateral damage seen with drugs that wipe out classes of immune cells across the body,» said Benoist, a professor of microbiology and immunobiology at HMS.
«Imaging of the joint could help evaluate the mechanism of a drug's therapeutic effect, and if a process turns out to be mediated by more than one chemoattractant, understanding the mechanism would allow the rational design of combination therapies to completely shut down critical steps in the process.»
For most of the past 20 years, therapies for hepatitis C relied on interferon drugs, which require regular injections for as long as one year and trigger miserable, flu - like side effects that prompt many patients to quit the regimen.
«These findings do not only contribute to new insights on the effects of anti-estrogen but also the potential of using miRNA for monitoring drug efficacy and for future RNA - based therapy developments.
Dr Elliott, who is part - funded by Parkinson's UK, said: «If this kind of drug proves to be successful in clinical trials, it would have the potential to bring long - lasting relief from PD symptoms and fewer side effects than existing levadopa therapy.»
By using insect activity monitors, the scientists assessed the effects of drug and gene therapy candidates on the flies» ability to move.
Alternative and combination therapies with niacin - like properties have helped lessen the intensity of the skin side effects accompanying the drug, but only mildly, and at the expense of cardio - protective qualities.
The FDA approved the combination of Mekinist and Tafinlar through its accelerated approval program, which allows the agency to approve drugs to treat a serious disease based on clinical data showing the therapy has a proven effect and clinical benefit to patients.
«Identifying a cancer driver is crucial for cancer treatment because it allows the use of targeted therapies, which have less side - effects than conventional chemotherapy drugs, against a particular protein,» said Kurokawa.
This therapeutic effect was enhanced by combining the Angiopoietin - 2 antibody with a so - called metronomic chemotherapy: In this kind of therapy, chemotherapeutic drugs are given continuously at much lower dose as in the classical high - dose chemotherapy.
Initiating drug therapy during pregnancy caused rapid declines in viral load, but more than 95 percent of women studied reported at least one side effect before delivery, which may lower adherence.
The map could be useful for working out how much of a drug's effect is due to a placebo response in clinical trials and for identifying good candidates for placebo therapy.
«Since doxorubicin is one of the cheapest drugs that is effective against many types of cancer but rarely used in colon cancer, the combination therapy could be highly effective in combating colon cancer while drastically lowering risk of cardiotoxic side effects.»
Take the example of antiretroviral drugs, where you got small effects with studies of individual drugs compared to two drug therapies that you really could not have detected without the right kind of study and right kind of statistics.
Although doctors have long incorporated personal information like family history into treatment plans, personalized medicine holds the promise of revolutionizing medical care by using knowledge of molecular biology and genetics that will allow more precise diagnoses, better diagnostic tests, greater predictability of disease course, more successful therapies by targeting the right treatments to the right patients, and improved patient safety by selecting drugs and their proper dosage to reduce adverse side effects.
To facilitate removal of the therapeutic stem cells from the brain at the conclusion of therapy, the researchers created cells that, in addition to TRAIL, express a viral gene called HSV - TK, which renders them susceptible to the effects of the antiviral drug ganciclovir.
Gwendolyn Thomas, assistant professor of exercise science, is the co-author of a groundbreaking article in the Obesity Journal (The Obesity Society, 2017) about the effects of exercise and physical activity on postmenopausal breast cancer survivors taking AIs — hormone - therapy drugs that stop the production of estrogen.
However, treatments of psychiatric disorders (e.g., drugs and cognitive behavior therapy) could not increase or decrease a specific connectivity between two regions, because these methods give broad effects on the global network.
Vaccines have shown promise in reducing the effects of drugs in research models but more needs to be learned about how to apply this therapy in the arc of addiction.
«These studies suggest the potential for dramatically reducing the dose of chemotherapy or radiation and thereby reducing the side effects of standard chemotherapy by enhancing the targeting of cancer therapies using HIV receptor blocking drugs.»
Watkins» work with glia, for example, has indicated that long - term opioid therapy may have an effect similar to that of chronic inflammation, causing glial cells to release an excess of cytokines that actually reduce the drug's effectiveness in blocking pain.
Moreover, the inhibitory effects of niclosamide on cancer stem cells provided further evidence for its consideration as a promising drug for cancer therapy.
Since stem cells are also critical for regeneration in the intestine, therapies that target these pathways may further help to design new drugs that reduce side effects associated with chemotherapy, radiotherapy or other causes of intestinal damage.
The side effects of immunotherapy are usually quite different from those of traditional cancer drugs used in therapies such as chemotherapy.
Pharmacogenomics, the study of how an individual's genetic variations impact the response to drugs, has emerged as an essential tool to optimize therapy and minimize the risk of adverse effects.
This is a critical field of study because the current drug therapies to lower IOP often are minimally effective and have unpleasant side effects.
«Drugs that block the effects of myofibroblasts on the electrical or mechanical properties of heart tissue or that coax them to revert to fibroblasts might be more effective than current therapies,» says Guy M. Genin, PhD, associate professor of mechanical engineering and materials science in WUSTL's School of Engineering & Applied Science, who is one of three co-primary investigators (PI) on the grant.
: We conclude that treatment of triple negative breast cancers with growth hormone - releasing hormone antagonists reduces tumor growth and potentiates the effects of cytotoxic therapy by nullifying drug resistance.
The co-delivery of small molecular drugs with nucleic acids can improve gene transfection efficiency, reduce side - effects of these drugs, and achieve the synergistic effect of drug and gene therapy for the more effective treatment of cancer.
We've seen drugs capable of turning white fat - storing tissue into brown, fat - burning tissue, but a new nanoparticle delivery system could significantly improve how such treatments are delivered, avoiding unwanted side effects often associated with such therapy.
By learning as much as possible about those unique changes, and developing specific drugs and therapies to target them, we at City of Hope believe many cancers can be defeated at the molecular level, often with fewer side effects compared to traditional chemotherapy and other treatments.
But many of the drugs currently being studied as epigenetic anticancer therapies may have indiscriminate effects.
The effect of gene therapy equaled that of a drug called VTS - 270, which has been evaluated in preclinical and clinical studies at numerous academic labs.
Slow down lymphoma growth modestly and show no effect on tumor regression; delay tumor recurrence with activation of p53; enhance tumor regression and inhibit tumor recurrence after alkylating drug therapy.
First of all, drugs have well - known side effects — ranging from toxicity to organs to addiction — while only a few side effects have been reported for mind - body therapies.
A study shows that humor therapy is as effective as popular antipsychotic meds in dealing with agitation in dementia and eliminates severe side effects of drugs
In general, the number and severity of adverse effects are related to the overall exposure, measured by length of therapy and blood drug concentration.
Past and current research projects have explored the effect of a diagnosis of breast cancer on lifestyle and mental health and adherence to lifestyle - based (i.e. nutrition and exercise) and drug therapy treatment programs.
I would just like to suggest that there are many alternative therapies that are far more gentle to your precious body, and don't carry the dangerous side - effects of most drugs.
Dr. Collin's consultation seeks to «integrate» conventional medical treatment with «alternative» therapies optimizing the health outcome using both approaches and minimizing adverse effects of drugs.